Difference between revisions of "MSK Biomarker Ctte"
Jump to navigation
Jump to search
Line 1: | Line 1: | ||
− | + | Co-chairs: Xiaojuan Li, PhD; Thomas M. Link, MD, PhD | |
− | + | <br />RSNA Staff Support: Susan Stanfa | |
* [https://docs.google.com/spreadsheets/d/e/2PACX-1vTtFdmro0ILLuaCHj65SltPX7AIp2nDeAj4UXWrZGgDTs5WrstIgEr0UTRxY3mSZ6ZnRi6bRuWWHsMt/pubhtml?gid=1066960490&single=true Roster] | * [https://docs.google.com/spreadsheets/d/e/2PACX-1vTtFdmro0ILLuaCHj65SltPX7AIp2nDeAj4UXWrZGgDTs5WrstIgEr0UTRxY3mSZ6ZnRi6bRuWWHsMt/pubhtml?gid=1066960490&single=true Roster] | ||
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK. | The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK. | ||
− | |||
− | |||
− | |||
==Meetings== | ==Meetings== | ||
'''Approved call summaries:''' | '''Approved call summaries:''' | ||
+ | *[[Media:2020_10-27_QIBA_MSK_BC_Call_Summary-FINAL.pdf|October 27, 2020]] | ||
*[[Media:2020_09-22_QIBA_MSK_BC_Call_Summary-FINAL.pdf|September 22, 2020]] | *[[Media:2020_09-22_QIBA_MSK_BC_Call_Summary-FINAL.pdf|September 22, 2020]] | ||
*[[Media:2020_07-28_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|July 28, 2020]] | *[[Media:2020_07-28_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|July 28, 2020]] | ||
− | |||
'''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | '''''[[MSK Biomarker Committee Call Summaries Archive]]''''' |
Revision as of 17:29, 26 January 2021
Co-chairs: Xiaojuan Li, PhD; Thomas M. Link, MD, PhD
RSNA Staff Support: Susan Stanfa
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.
Meetings
Approved call summaries:
MSK Biomarker Committee Call Summaries Archive
Working Documents
- QIBA MSK Profile 2020-01-28: MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease